A Nurse-Driven Outpatient Clinic for Thiopurine-Treated Inflammatory Bowel Disease Patients Reduces Physician Visits and Increases Follow-Up Efficiency

被引:4
作者
Lopez, Maria [1 ]
Dosal, Angelina [1 ]
Villoria, Albert [2 ]
Moreno, Laura [1 ]
Calvet, Xavier [2 ]
机构
[1] Hosp Sabadell, Infermeria, Sabadell, Barcelona, Spain
[2] Univ Autonoma Barcelona, Hosp Sabadell, Serv Aparell Digestiu, CIBERehd,Inst Salud Carlos 3,Inst Univ Parc Tauli, Sabadell 08208, Barcelona, Spain
关键词
RANDOMIZED CONTROLLED-TRIAL; AZATHIOPRINE; 6-MERCAPTOPURINE; MANAGEMENT;
D O I
10.1097/SGA.0000000000000103
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Patients on thiopurine therapy need frequent monitoring to prevent drug adverse events. To describe the structure and main results of a nurse-driven outpatient clinic (NDOC) program for the follow-up of patients receiving treatment with thiopurine immunosuppressants, we retrospectively reviewed patients' clinical charts on thiopurine drugs, azathioprine (AZA), and 6-mercaptopurine. We evaluated the efficacy of the NDOC by comparing the number of physician visits and the adequacy of laboratory controls for each patient before and after inclusion in the program. From January 2006 to December 2008, 179 patients were included. Of these, 102 had received thiopurines for at least 1 year before the start of the NDOC. Mean age was 42 +/- 15 years; 83 were female. In all, 137 of the 179 patients (76%) had Crohn disease. AZA was the most frequent drug used (97%). Mean time of follow-up was 2.03 +/- 0.9 years. Implementation of this program decreased the number of physician visits per year-from 4.6 +/- 1.9 to 2.4 +/- 1.3 (p < .001)-and the number of periods longer than 4 months without laboratory control (from 68% to 45%; p = .01). Leucopenia episodes and complications did not differ significantly before and after the start of the NDOC. Nurse-driven follow-up of these patients reduces physician visits while improving tightness of the follow-up.
引用
收藏
页码:116 / 120
页数:5
相关论文
共 15 条
  • [1] [Anonymous], 2000, Cochrane Database Syst Rev, DOI DOI 10.1002/14651858.CD000067
  • [2] [Anonymous], COCHRANE DATABASE SY, DOI 10.1002/14651858.CD000545
  • [3] Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis
    Ardizzone, S
    Maconi, G
    Russo, A
    Imbesi, V
    Colombo, E
    Porro, GB
    [J]. GUT, 2006, 55 (01) : 47 - 53
  • [4] Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease
    Calvet, Xavier
    Gallardo, Olga
    Coronas, Ramon
    Casellas, Francesc
    Montserrat, Antonia
    Torrejon, Antonio
    Vergara, Mercedes
    Campo, Rafel
    Brullet, Enric
    [J]. INFLAMMATORY BOWEL DISEASES, 2006, 12 (08) : 692 - 696
  • [5] Guidelines for the management of inflammatory bowel disease in adults
    Carter, MJ
    Lobo, AJ
    Travis, SPL
    [J]. GUT, 2004, 53 : v1 - v16
  • [6] BONE-MARROW TOXICITY CAUSED BY AZATHIOPRINE IN INFLAMMATORY BOWEL-DISEASE - 27 YEARS OF EXPERIENCE
    CONNELL, WR
    KAMM, MA
    RITCHIE, JK
    LENNARDJONES, JE
    [J]. GUT, 1993, 34 (08) : 1081 - 1085
  • [7] Safety of thiopurines in the treatment of inflammatory bowel disease
    de Jong, DJ
    Derijks, LJJ
    Naber, AHJ
    Hooymans, PM
    Mulder, CJJ
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2003, 38 : 69 - 72
  • [8] Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: A review
    Gisbert, Javier P.
    Gomollon, Fernando
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (07) : 1783 - 1800
  • [9] RANDOMIZED CONTROLLED TRIAL OF AZATHIOPRINE WITHDRAWAL IN ULCERATIVE-COLITIS
    HAWTHORNE, AB
    LOGAN, RFA
    HAWKEY, CJ
    FOSTER, PN
    AXON, ATR
    SWARBRICK, ET
    SCOTT, BB
    LENNARDJONES, JE
    [J]. BRITISH MEDICAL JOURNAL, 1992, 305 (6844) : 20 - 22
  • [10] CONTROLLED TRIAL OF AZATHIOPRINE IN CHRONIC ULCERATIVE-COLITIS
    KIRK, AP
    LENNARDJONES, JE
    [J]. BRITISH MEDICAL JOURNAL, 1982, 284 (6325) : 1291 - 1292